GSK3 α/β: A Novel Therapeutic Target for Neuroendocrine Tumors?
Conclusion: Our data provide new insights into the role of GSK3 α/β in NETs and suggest that GSK3α/β inhibition could be a novel therapeutic option in NETs, especially in combination with lovastatin or 5-FU, depending on tumor entity.Neuroendocrinology
Source: Neuroendocrinology - Category: Endocrinology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Endocrinology | Epithelial Cancer | Lovastatin | Neurology | Study